BrainStorm, FDA to discuss plans for Phase 3b trial of NurOwn on Dec. 6
The U.S. Food and Drug Administration (FDA) soon will meet with BrainStorm Cell Therapeutics to discuss the company’s plans…
Articles by Andrea Lobo, PhD
£14.5M awarded toward ALS, other neurodegenerative disease projects
A partnership between LifeArc and the UK Dementia Research Institute (UK DRI) is awarding £14.5 million (about $18.2 million)…
High uric acid levels may protect against cognitive decline in ALS
Having higher blood levels of uric acid may prevent or delay the decline in cognitive function in people with…
Top-line results of PARADIGM trial into PrimeC expected by year’s end
NeuroSense Therapeutics is planning to soon announce top-line safety and efficacy results from its PARADIGM trial, which is…
Survey offers look at life, treatment priorities of those living with ALS
People with amyotrophic lateral sclerosis (ALS) report significant changes in lifestyle after their diagnosis, but still have an acceptable…
FDA names CB03, aiming to protect neurons, an orphan drug for ALS
The U.S. Food and Drug Administration (FDA) has given orphan drug designation to CB03, Zhimeng Biopharma’s small molecule…
BrainStorm drops FDA application for NurOwn
BrainStorm Cell Therapeutics is withdrawing the application requesting U.S. approval of its cell-based therapy NurOwn for the treatment…
PrimeC, potential ALS therapy, earns patents in Europe, Japan, Israel
NeuroSense Therapeutics has received key patents in Europe, Japan, and Israel covering the use of PrimeC, its investigational,…
Aruna Bio’s AB126 eased inflammation in ALS mouse model
Aruna Bio‘s investigational therapy AB126 significantly eased inflammation in the spinal cord and extended survival in a mouse…
FDA clears first-in-human clinical trial of AKV9 in healthy volunteers
Akava Therapeutics will soon launch a Phase 1 clinical trial to test AKV9, its investigational therapy for amyotrophic…